gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 15 Apr 2015.

Interleukin 6 receptor

IL-6R, interleukin-6 receptor, gp80, IL-6Ralpha
This gene encodes a subunit of the interleukin 6 (IL6) receptor complex. Interleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. The IL6 receptor is a protein complex consisting of this protein and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta), a receptor subunit also shared by many other cytokines. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. A pseudogene of this gene is found on chromosome 9.[provided by RefSeq, May 2011] (from NCBI)
Top mentioned proteins: Interleukin-6, NMDA receptor, CAN, V1a, STAT3
Papers using IL-6R antibodies
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Sesti Giorgio, In PLoS ONE, 1997
... used anti-cytokines antibodies against IL-1ß, IL-6, TNFα, IFNγ, and anti-cytokine receptor antibodies against IL-1R1, IL-1R2, IL-6R, TNF-R1, IFN-Rα, IFN-Rß (Santa Cruz Biotechnology, Santa Cruz, CA); guinea ...
Papers on IL-6R
Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Okamoto et al., Tokyo, Japan. In Mol Carcinog, 09 May 2015
It was shown that CCC recently was characterized by specific upregulation of the IL-6/IL-6R-signal transducer and activator of transcription 3 (Stat3) signaling pathway.
Secreted Frizzled-related protein 3 (sFRP3)-mediated suppression of Interleukin-6 receptor release by A disintegrin and Metalloprotease 17 (ADAM17) is abrogated in the osteoarthritis-associated rare double variant of sFRP3.
Lorenzen et al., In Biochem J, 07 May 2015
This study demonstrates a novel function of sFRP3 in suppression of the enzymatic activity of ADAM17 which results in the inhibition of ADAM17-meditated interleukin-6 receptor (IL-6R) shedding.
Radiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis.
Kobayashi et al., Hakodate, Japan. In Pediatr Int, 30 Apr 2015
Clinical remission was achieved, however, after switching the biologic agent to tocilizumab, a humanized monoclonal antibody to interleukin-6 receptor.
Interleukin-6 mediates exercise preconditioning against myocardial ischemia reperfusion injury.
Quindry et al., Colombia. In Am J Physiol Heart Circ Physiol, 27 Apr 2015
In Aim 1, serum IL-6 and IL-6R, gastrocnemius and myocardial IL-6R were increased following exercise in C57 mice only.
Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro.
Su et al., Harbin, China. In Thromb Res, 18 Apr 2015
All of the above outcomes were reversed to a variable extent by anti-IL-6R and anti-TNFα antibodies.
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.
Rose-John et al., Kiel, Germany. In Curr Opin Immunol, 04 Apr 2015
However, a plethora of studies in the last decade has convincingly shown that only signaling via the soluble IL-6R (trans-signaling) accounts for the deleterious effects of IL-6, whereas classic signaling via the membrane-bound receptor is essential for the regenerative and anti-bacterial effects of IL-6 (classic signaling).
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Hill et al., Brisbane, Australia. In Lancet Oncol, Dec 2014
Immune reconstitution was preserved in recipients of interleukin-6 receptor inhibition, but qualitatively modified with suppression of known pathogenic STAT3-dependent pathways.
Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production.
Mauri et al., Udine, Italy. In Nat Med, Nov 2014
Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specifically on B cells have a reduced number of IL-10-producing B cells and develop exacerbated arthritis compared to control animals.
Interleukin-6 and its receptors: a highly regulated and dynamic system.
Garbers et al., Kiel, Germany. In Cytokine, Nov 2014
IL-6 induces intracellular signaling pathways after binding to its membrane-bound receptor (IL-6R), which is only expressed on hepatocytes and certain subpopulations of leukocytes (classic signaling).
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Grupp et al., Australia. In N Engl J Med, Nov 2014
Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.
Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Berk et al., Geelong, Australia. In Expert Opin Ther Targets, May 2014
The pro-inflammatory effects of IL-6 are predominantly mediated by IL-6 trans-signalling via the sIL-6R, whereas IL-6R membrane signalling has anti-inflammatory effects.
Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Grupp et al., Philadelphia, United States. In Cancer J, Mar 2014
One approach we have developed targets IL-6, a prominent cytokine in CRS, using the IL-6R antagonist tocilizumab.
Interleukin-6: possible biological roles during exercise.
Dela et al., Rīga, Latvia. In Ejss (champaign), 2013
Interleukin-6 (IL-6) is a multifunctional cytokine that exerts its modulatory effects on cells that express membrane bound IL-6 receptors; however, IL-6 in a complex with soluble IL-6R can bind to any cell that express glycoprotein 130 (gp130).
Metalloproteinases and their natural inhibitors in inflammation and immunity.
Weiss et al., Toronto, Canada. In Nat Rev Immunol, 2013
Together with their endogenous inhibitors TIMPs (tissue inhibitor of metalloproteinases), these enzymes regulate signalling downstream of the tumour necrosis factor receptor and the interleukin-6 receptor, as well as that downstream of the epidermal growth factor receptor and Notch, which are all pertinent for inflammatory responses.
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
PRCSG et al., Roma, Italy. In N Engl J Med, 2013
METHODS: We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the weight was ≥30 kg or 12 mg per kilogram if the weight was <30 kg) or placebo given intravenously every 2 weeks during the 12-week, double-blind phase.
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma.
National Heart et al., Winston-Salem, United States. In J Allergy Clin Immunol, 2012
The IL6R coding SNP rs2228145 (Asp358Ala) is a potential modifier of lung function in subjects with asthma and might identify subjects at risk for more severe asthma.
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
Shin et al., South Korea. In Int J Oncol, 2012
IL-6R is present in cancer stem cells and has an important role in the proliferation
Interleukin-6 receptor α is co-localised with melanin-concentrating hormone in human and mouse hypothalamus.
Jansson et al., Göteborg, Sweden. In J Neuroendocrinol, 2012
Il6r alpha is co-localized with melanin-concentrating hormone in mouse hypothalamus.
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Danesh et al., In Lancet, 2012
We assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.
Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation.
Banas et al., Regensburg, Germany. In Cytokine, 2012
Elevated urinary concentrations of IL6, sIL6R, TNFR1 and sVCAM-1 clearly indicate an early acute transplant rejection.
share on facebooktweetadd +1mail to friends